{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:51:19Z","timestamp":1775580679411,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Literature regarding prognostic relevance of CD20 antigen expression among paediatric B\u2010lineage acute lymphoblastic leukaemia (B\u2010ALL) patients is sparse and contradictory. We analysed clinical laboratory parameters and survival characteristics pertinent to CD20 expression among 224 treatment\u2010na\u00efve paediatric B\u2010ALL patients. 50% patients had CD20 expression (CD20+ B\u2010ALL). There was no difference in the clinical &amp; laboratory presentation and end of induction measurable residual disease (EOI\u2010MRD) status according to CD20 expression. As compared to CD20\u2212 B\u2010ALL patients, CD20+ B\u2010ALL patients had two times more relapse (16% vs. 29%, <jats:italic>p<\/jats:italic>\u2009=\u20090.034), inferior relapse\u2010free survival (79% vs. 66%, <jats:italic>p<\/jats:italic>\u2009=\u20090.025) but no difference in overall survival (75% vs. 69%, <jats:italic>p<\/jats:italic>\u2009=\u20090.126). Similar to high\u2010risk NCI status and EOI\u2010MRD positivity, CD20 expression was an independent predictor for inferior relapse\u2010free survival (HR: 1.860, 95% CI: 1.008\u20133.432, <jats:italic>p<\/jats:italic>\u2009=\u20090.047). Compared to baseline, there was a significant increase in CD20\u2010expressing EOI\u2010residual blasts among CD20\u2212 B\u2010ALL patients (5% vs. 13%, <jats:italic>p<\/jats:italic>\u2009=\u20090.001). EOI residual blasts of both CD20+ and CD20\u2212 patients had three times increased normalized CD20 expression intensity (nCD20), with the intensity among CD20\u2212 B\u2010ALL patients reaching the pretreatment nCD20 of CD20+ B\u2010ALL patients (4.9 vs. 3.6, <jats:italic>p<\/jats:italic>\u2009=\u20090.666). Rituximab can be considered in managing EOI\u2010MRD\u2010positive CD20\u2212 B\u2010ALL patients as the residual blasts of these patients have quantitative and qualitative increases in CD20 expression.<\/jats:p>","DOI":"10.1111\/bjh.19370","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T05:34:39Z","timestamp":1709703279000},"page":"1367-1374","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Relevance of <scp>CD20<\/scp> antigen expression among paediatric patients with B\u2010lineage acute lymphoblastic leukaemia"],"prefix":"10.1111","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0851-886X","authenticated-orcid":false,"given":"Karthik","family":"Bommannan","sequence":"first","affiliation":[{"name":"Department of Oncopathology Cancer Institute (W.I.A.)  Chennai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhansi Rani","family":"Arumugam","sequence":"additional","affiliation":[{"name":"Department of Oncopathology Cancer Institute (W.I.A.)  Chennai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkatraman","family":"Radhakrishnan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Institute (W.I.A.)  Chennai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"Sundersingh","sequence":"additional","affiliation":[{"name":"Department of Oncopathology Cancer Institute (W.I.A.)  Chennai India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.4103\/2278-330X.187591"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016709"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.068288"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1179\/102453312X13221316477741"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00580-017-2469-4"},{"issue":"11","key":"e_1_2_15_7_1","first-page":"3960","article-title":"Prognostic significance of fluorescence intensity of surface marker expression in childhood B\u2010precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study","volume":"89","author":"Borowitz MJ","year":"1997","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041451"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06033-1"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1625043"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13436"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21518"},{"issue":"10","key":"e_1_2_15_13_1","first-page":"3982","article-title":"CD20 up\u2010regulation in pediatric B\u2010cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti\u2010CD20 directed immunotherapy","volume":"112","author":"Dworzak MN","year":"2008","journal-title":"Blood, the Journal of the American Society of Hematology"},{"issue":"25","key":"e_1_2_15_14_1","first-page":"6330","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B\u2010lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas DA","year":"2009","journal-title":"Blood, the Journal of the American Society of Hematology"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000256"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605085"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288\u2010023\u201001699\u20102"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13436"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21765"},{"issue":"6","key":"e_1_2_15_20_1","first-page":"571","article-title":"Rituximab added to standard chemotherapy and its effect on minimal residual disease during induction in CD20 positive pediatric acute lymphoblastic leukemia: a pilot RCT","volume":"11","author":"Gupta AK","year":"2021","journal-title":"Am J Blood Res"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1425389"},{"issue":"26","key":"e_1_2_15_22_1","first-page":"4010","article-title":"Monoclonal antibodies in acute lymphoblastic leukemia","volume":"125","author":"Jabbour E","year":"2015","journal-title":"Blood, the Journal of the American Society of Hematology"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123374"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.414"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9456"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403559"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T15:35:43Z","timestamp":1712763343000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/bjh.19370"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19370","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"2023-12-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}